Propanc Biopharma shares surge 31.99% intraday after filing provisional patents for resistant cancer and fibrosis treatments.

Propanc Biopharma surged 31.99% intraday after announcing the submission of two provisional patents for novel treatments targeting resistant cancer and fibrosis, filed via its Australian subsidiary. The patents, developed through joint research with Spanish universities, mark the first expansion of its lead product, PRP, into fibrosis, a high-unmet-need chronic condition. CEO James Nathanielsz highlighted the patents as a “significant turning point,” with a planned 2026 Phase 1b First-In-Human study to define PRP’s therapeutic dose. The news underscores Propanc’s potential to commercialize PRP across multiple disease areas, positioning it as a non-cytotoxic therapy addressing both oncology and fibrotic disorders. The filing also signals global IP strategy, with plans to pursue patents in key jurisdictions, enhancing long-term commercial prospects.